Alyeska Investment Group L.P. Lowers Stock Position in ASP Isotopes Inc. (NASDAQ:ASPI)

Alyeska Investment Group L.P. decreased its position in ASP Isotopes Inc. (NASDAQ:ASPI) by 53.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 347,022 shares of the company’s stock after selling 400,000 shares during the period. Alyeska Investment Group L.P. owned 0.49% of ASP Isotopes worth $1,572,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its stake in ASP Isotopes by 14.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 21,646 shares of the company’s stock valued at $99,000 after acquiring an additional 2,757 shares during the last quarter. Russell Investments Group Ltd. grew its stake in ASP Isotopes by 56.3% during the fourth quarter. Russell Investments Group Ltd. now owns 10,221 shares of the company’s stock valued at $46,000 after acquiring an additional 3,682 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of ASP Isotopes by 31.4% in the third quarter. JPMorgan Chase & Co. now owns 22,196 shares of the company’s stock worth $62,000 after purchasing an additional 5,307 shares during the period. Hanson & Doremus Investment Management purchased a new stake in shares of ASP Isotopes in the 4th quarter valued at about $27,000. Finally, Wells Fargo & Company MN raised its stake in ASP Isotopes by 57.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,472 shares of the company’s stock valued at $111,000 after purchasing an additional 8,925 shares in the last quarter. Institutional investors own 16.80% of the company’s stock.

ASP Isotopes Stock Up 1.0 %

Shares of NASDAQ:ASPI opened at $5.50 on Wednesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.54 and a current ratio of 7.55. The firm has a fifty day moving average of $4.86 and a 200 day moving average of $5.38. ASP Isotopes Inc. has a 52-week low of $1.86 and a 52-week high of $9.33. The firm has a market capitalization of $413.14 million, a PE ratio of -9.02 and a beta of 3.40.

Insider Activity

In other ASP Isotopes news, CEO Paul Elliot Mann sold 316,667 shares of the business’s stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $5.75, for a total value of $1,820,835.25. Following the completion of the sale, the chief executive officer now directly owns 7,948,787 shares of the company’s stock, valued at $45,705,525.25. The trade was a 3.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Robert Ainscow sold 66,666 shares of the stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $5.75, for a total value of $383,329.50. Following the sale, the chief operating officer now owns 1,553,326 shares of the company’s stock, valued at $8,931,624.50. This represents a 4.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 766,667 shares of company stock worth $4,358,502. 21.40% of the stock is currently owned by insiders.

ASP Isotopes Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.